Authors (reference) | Li [10] | Röllig [11] | Desikan [12] | Daver [13] | Bollino [14] |
---|---|---|---|---|---|
Regimen | VEN + Cladribine + Ara-C | VEN + HAM | VEN + FLAG-IDA | VEN + AZA + PVEK | VEN + PegC |
Study type | N/A | Phase-I/II | Phase IIb | Phase 1b/II | Phase Ib |
NCT number | NCT05190549 | NCT04330820 | N/A | NCT04086264 | NCT04666649 |
Study period | 2021–2022 | 2020–2022 | N/A | N/A | N/A |
Age range (years) | 16–68 | 40–70 | 18–68 | 25–82 | 24–76 |
Patients number | 21 | 12 | 33 | 71 | 11 |
Response rate | ORR 90.5%, CR/CRi 28.6% | CR/CRi 92% | ORR 60% | ORR 51% | ORR 64% |
Grade ≥ 3 AEs | N/A | 0 | N/A | Ferbrile neutropenia 24% | 0 |
Follow-up (months) | N/A | N/A | 15.8 | N/A | N/A |
Survival | Median OS and EFS not reached, estimated 1-year OS 91.7%, estimated 1-year EFS 74.9% | N/A | Median OS 27 months, median DOR not reached. Six-month OS 69%, 12-month OS 60% | N/A | N/A |